Lowering risk of death from prostate cancer AND cardiovascular disease

Based on a specific case study, a new paper in Circulation by a group of clinicians at Vanderbilt University Medical Center describes their program designed to reduce risk of death from cardiovascular disease for prostate cancer patients on androgen deprivation therapy (ADT). … READ MORE …

EBRT works better with ADT for intermediate- and high-risk prostate cancer

The EORTC trial 22991 was designed and implemented to compare external beam radiation therapy (EBRT) + short-term androgen deprivation therapy (ADT) to EBRT alone as first-line therapy in patients with intermediate- and high-risk prostate cancer. … READ MORE …

Quality of life data and the CHAARTED trial

As regular readers will be aware, the data from the CHAARTED trial were the first to show that combining androgen deprivation (ADT) with docetaxel chemotherapy has a significant, life-extending benefit in at least some men newly diagnosed with metastatic prostate cancer. … READ MORE …

Prostate cancer, cardiovascular disease, and the role of ADT

A new trial to be discussed at the Genitourinary Cancers Symposium is the RADICAL-PC trial, designed to give us a greater understanding of the roles of androgen deprivation (ADT) and other factors in causing cardiovascular disease in high-risk prostate cancer patients. … READ MORE …

Full data on ADT + chemotherapy from the STAMPEDE trial now published

Back in May 2015, James et al. reported on the survival benefits associated with androgen deprivation therapy (ADT) + docetaxel-based chemotherapy compared to ADT alone as first-line therapy for treatment-naive men initially diagnosed with metastatic prostate cancer. … READ MORE …

Is ADT giving you Alzheimer’s disease?

A newly published article in the Journal of Clinical Oncology has demonstrated an association between treatment with androgen deprivation therapy (ADT) and risk for diagnosis with Alzheimer’s disease among prostate cancer patients at an average of 3 years of follow-up. However, … READ MORE …

Meta-analysis of data on ADT + docetaxel as first-line therapy for metastatic prostate cancer

Another paper at the European Cancer Congress this year has given us meta-analyses of data from studies of docetaxel chemotherapy + standard of care (i.e., some form of androgen deprivation therapy or ADT) in treatment of men newly diagnosed with metastatic (M1) and advanced but non-metastatic (M0) prostate cancer. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,369 other followers